Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens: An individual patient data meta-analysis from randomized, placebo-controlled trials

Hypertension

Volumn 56, Issue 3, 2010, Pages 533-539

  Bell, Katy J L ^a   Hayen, Andrew ^a   MacAskill, Petra ^a   Craig, Jonathan C ^a,b   Neal, Bruce C ^c   Fox, Kim M ^d   Remme, Willem J ^e   Asselbergs, Folkert W ^f   Van Gilst, Wiek H ^g   MacMahon, Stephen ^c   Remuzzi, Giuseppe ^h   Ruggenenti, Piero ^h   Teo, Koon K ⁱ   Irwig, Les ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e Sticares Cardiovascular Research Foundation   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h OSPEDALI RIUNITI   (Italy)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

angiotensin converting enzyme inhibitors; blood pressure; cardiovascular disease; models; reproducibility of results; statistical; stroke; treatment outcome

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; META ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; REPRODUCIBILITY; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 77955983000     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.152421     Document Type: Article

References (25)

1. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
2. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
3. Bell KJL, Irwig L, Craig JC, Macaskill P. Use of randomized trials to decide when to monitor response to new treatment. BMJ. 2008;336:361-365.
4. Marshall T. Measuring blood pressure: the importance of understanding variation. Rev Bras Hipertens. 2005;12:75-82.
5. Task Force for the Management of Arterial Hypertension of the ESH and of the ESC. 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
6. Chobanian AV, Bakris GR, Black HL, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252. (Pubitemid 37553153)
7. Blood Pressure Lowering Treatment Trialists' Collaboration, World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens. 1998;16:127-137.
8. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration, collaborating trials. Available at: http://www.george.org.au/bplttc/collaboration.html. Accessed 1 June 2008.
9. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
10. The PEACE Trial Investigators. Angiotensin converting enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351: 2058-2068.
11. Marre M, Lievre M, Chatellier G, Mann J, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR Study). BMJ. 2004;328:495.
12. EUROPA Trial Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients wiht stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre tiral (the EUROPA Study). Lancet. 2003;362:782-788.
13. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial); a randomised controlled trial. Lancet. 2007;370:829-840.
14. PROGRESS Collaboration Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
15. Asselbergs FW, Diercks GFH, Hillege HL, Van Boven AJ, Janssen WMT, Voors AA, de Zeeuw D, de Jong PE, Van Veldhuisen DJ, Van Gilst WH, for the Prevention of Renal and Vascular Endstage Disease Intervention Trial Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
16. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H, for the PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438-443.
17. Ruggenenti P, Fassi A, Ileva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, for the Bergamo Neph-rologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
18. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
19. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy. J Clin Epidemiol. 2009;62:650-659.
20. Keenan K, Hayen A, Neal B, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ. 2009;338:b1492.
21. Hebel JR, Apostolidesp AY, Dischingerg P, Entwisle G, Su S. Within-person variability in diastolic blood pressure for a cohort of normo-tensives. J Chronic Dis. 1980;33:745-750.
22. Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet. 2002; 359:2271-2273.
23. Jackson R, Lawes C, Bennet D, Milne R, Roders A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365:434-441.
24. Marshall T. Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. Med Decis Making. 2006;26:624-632.
25. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.